Skip to main content
Enter the terms you wish to search for.
Select Search Option
This Site
All WCM Sites
Directory
Menu
Weill Cornell Medicine
Care
Discover
Teach
Jill Roberts Center for Inflammatory Bowel Disease
Explore this Website
Home
About Us
Toggle About Us menu options
Clinical Staff
Research Staff
Contact Us
Newsworthy
Toggle Newsworthy menu options
News and Announcements
Patient Care
Toggle Patient Care menu options
Clinical Services
FAQs
For Your Visit
COVID-19 Information
Nutrition Science
Toggle Nutrition Science menu options
Nutrition FAQs
Food Intolerances
News in IBD Nutrition
Research and Clinical Trials
Toggle Research and Clinical Trials menu options
Clinical Trials
Publications
Weill Cornell Medicine
Care
Discover
Teach
Home
About Us
Newsworthy
Patient Care
Nutrition Science
Research and Clinical Trials
Home
Publications
Publications
Clinical Trials
Publications
Publications
Found 10 results
Author
[
Title
]
Type
Year
Filters:
Author
is
Feagan, Brian G
[Clear All Filters]
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
B
Battat R
,
Ma C
,
Jairath V
,
Khanna R
,
Feagan BG
. 2019.
Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative Colitis.
.
Drug Saf. 42(5):617-632.
D
Dulai PS
,
Boland BS
,
Singh S
,
Chaudrey K
,
Koliani-Pace JL
,
Kochhar G
,
Parikh MP
,
Shmidt E
,
Hartke J
,
Chilukuri P
et al.
. 2018.
Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.
.
Gastroenterology. 155(3):687-695.e10.
Dulai PS
,
Singh S
,
Casteele NVande
,
Meserve J
,
Winters A
,
Chablaney S
,
Aniwan S
,
Shashi P
,
Kochhar G
,
Weiss A
et al.
. 2020.
Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis.
.
Clin Gastroenterol Hepatol. 18(13):2952-2961.e8.
E
Sandborn WJ
,
Feagan BG
,
Loftus EV
,
Peyrin-Biroulet L
,
Van Assche G
,
D'Haens G
,
Schreiber S
,
Colombel J-F
,
Lewis JD
,
Ghosh S
et al.
. 2020.
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.
.
Gastroenterology. 158(8):2123-2138.e8.
H
Battat R
,
Duijvestein M
,
Guizzetti L
,
Choudhary D
,
Boland BS
,
Dulai PS
,
Parker CE
,
Nguyen TM
,
Singh S
,
Casteele NVande
et al.
. 2019.
Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
.
Am J Gastroenterol. 114(5):733-745.
I
Dulai PS
,
Battat R
,
Barsky M
,
Nguyen NH
,
Ma C
,
Narula N
,
Mosli M
,
Casteele NVande
,
Boland BS
,
Prokop L
et al.
. 2020.
Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors.
.
Am J Gastroenterol. 115(6):885-894.
Ma C
,
Battat R
,
Dulai PS
,
Parker CE
,
Sandborn WJ
,
Feagan BG
,
Jairath V
. 2019.
Innovations in Oral Therapies for Inflammatory Bowel Disease.
.
Drugs. 79(12):1321-1335.
Ma C
,
Sedano R
,
Almradi A
,
Casteele NVande
,
Parker CE
,
Guizzetti L
,
Schaeffer DF
,
Riddell RH
,
Pai RK
,
Battat R
et al.
. 2021.
An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials.
.
Gastroenterology. 160(7):2291-2302.
R
Sandborn WJ
,
Feagan BG
,
Fedorak RN
,
Scherl E
,
Fleisher MR
,
Katz S
,
Johanns J
,
Blank M
,
Rutgeerts P
. 2008.
A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.
.
Gastroenterology. 135(4):1130-41.
S
Sedano R
,
Hogan M
,
Nguyen TM
,
Chang J
,
Zou GY
,
Macdonald JK
,
Casteele NVande
,
Hanzel J
,
Crowley E
,
Battat R
et al.
. 2021.
Systematic review and Meta-analysis: Clinical, Endoscopic, Histologic and Safety Placebo Rates in Induction and Maintenance trials of Ulcerative Colitis.
.
J Crohns Colitis.